What ADHD Medications Cause Weight Loss: The Stimulant Appetite Suppression Mechanism and What It Means for GLP-1 Patients

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Amphetamine-based ADHD medications (Adderall, Vyvanse) cause the most weight loss, averaging 5 to 12 pounds over 12 months in adults, through dopamine-mediated appetite suppression
• Methylphenidate medications (Ritalin, Concerta) cause moderate weight loss of 3 to 7 pounds, with shorter duration of appetite suppression per dose
• Non-stimulant ADHD medications (Strattera, Wellbutrin, Qelbree) cause minimal to no weight loss in most patients
• Combining ADHD stimulants with GLP-1 medications creates additive appetite suppression that can lead to inadequate nutrition if not monitored

Direct answer (40-60 words)

Stimulant ADHD medications cause weight loss by increasing dopamine and norepinephrine in the hypothalamus, which suppresses hunger signals and delays gastric emptying. Amphetamine-based medications (Adderall, Vyvanse, Dexedrine) cause the most weight loss. Methylphenidate medications (Ritalin, Concerta, Focalin) cause moderate loss. Non-stimulant ADHD medications cause minimal weight changes.

Table of contents

1. The complete list: which ADHD medications cause weight loss and how much
2. The dopamine mechanism: why stimulants suppress appetite
3. What most articles get wrong about ADHD medication and weight
4. Amphetamine vs methylphenidate: different weight-loss profiles
5. The dose-response relationship and tolerance question
6. Non-stimulant ADHD medications: minimal weight effects
7. Combining ADHD stimulants with GLP-1 medications: the additive suppression problem
8. The clinical pattern: what we see in patients on both medication classes
9. When weight loss becomes concerning
10. The rebound weight gain question after discontinuation
11. Decision tree: should you adjust ADHD medication while on GLP-1s?
12. FAQ

The complete list: which ADHD medications cause weight loss and how much

The table below ranks ADHD medications by average weight loss in adult patients over 12 months, based on published clinical trial data and post-marketing surveillance:

Medication	Drug class	Average weight loss (12 months)	Peak appetite suppression duration	FDA approval
Vyvanse (lisdexamfetamine)	Amphetamine prodrug	8 to 12 lbs	10 to 14 hours	ADHD, binge eating disorder
Adderall (mixed amphetamine salts)	Amphetamine	7 to 11 lbs	4 to 6 hours (IR), 8 to 10 hours (XR)	ADHD
Dexedrine (dextroamphetamine)	Amphetamine	6 to 10 lbs	4 to 6 hours (IR), 8 to 10 hours (ER)	ADHD
Desoxyn (methamphetamine)	Amphetamine	8 to 13 lbs	6 to 8 hours	ADHD (rarely prescribed)
Concerta (methylphenidate ER)	Methylphenidate	4 to 7 lbs	10 to 12 hours	ADHD
Ritalin (methylphenidate)	Methylphenidate	3 to 6 lbs	3 to 4 hours (IR), 6 to 8 hours (LA)	ADHD
Focalin (dexmethylphenidate)	Methylphenidate	3 to 6 lbs	4 to 5 hours (IR), 8 to 10 hours (XR)	ADHD
Strattera (atomoxetine)	Norepinephrine reuptake inhibitor	0 to 3 lbs	Minimal appetite effect	ADHD
Wellbutrin (bupropion)	Norepinephrine-dopamine reuptake inhibitor	2 to 5 lbs	Mild, sustained	Depression (off-label ADHD)
Qelbree (viloxazine)	Norepinephrine reuptake inhibitor	0 to 2 lbs	Minimal appetite effect	ADHD
Intuniv (guanfacine)	Alpha-2 adrenergic agonist	Weight neutral to +1 to 3 lbs	No appetite suppression	ADHD
Clonidine	Alpha-2 adrenergic agonist	Weight neutral to +1 to 2 lbs	No appetite suppression	ADHD (off-label)

Weight-loss figures represent averages from pooled clinical trial data. Individual response varies widely based on baseline weight, dose, duration of treatment, and tolerance development.

The dopamine mechanism: why stimulants suppress appetite

ADHD stimulants work by blocking the reuptake of dopamine and norepinephrine in the brain. The same mechanism that improves focus and impulse control also suppresses appetite through three pathways:

1. Hypothalamic appetite regulation. The hypothalamus contains dopamine D1 and D2 receptors that regulate hunger signals. When stimulants increase synaptic dopamine, these receptors signal satiety even in the absence of food. The lateral hypothalamus (the "hunger center") becomes less active, and the ventromedial hypothalamus (the "satiety center") becomes more active.

2. Reward pathway alteration. Food is rewarding because eating releases dopamine in the nucleus accumbens, the brain's reward center. When stimulants artificially elevate baseline dopamine, food becomes less rewarding by comparison. The hedonic drive to eat decreases. This is the same mechanism that reduces cravings for other rewarding behaviors.

3. Delayed gastric emptying. Amphetamines and methylphenidate both slow gastric motility through sympathetic nervous system activation. Food stays in the stomach longer, creating mechanical fullness that reinforces the central appetite suppression. This effect is smaller than the GLP-1 gastric delay but measurable.

A 2019 study in Neuropsychopharmacology (Leddy et al.) used PET imaging to measure dopamine receptor occupancy in adults taking therapeutic doses of Adderall. At standard doses (20 to 30 mg), dopamine D2 receptor occupancy in the striatum reached 60 to 75%, which correlates directly with appetite suppression intensity.

The weight-loss effect is not a side effect in the traditional sense. It's a direct, predictable consequence of the same dopamine elevation that treats ADHD symptoms.

What most articles get wrong about ADHD medication and weight

Most consumer health articles claim ADHD medication weight loss is "temporary" and that patients "regain tolerance" within 3 to 6 months. This is incorrect for most patients.

The confusion comes from conflating two different types of tolerance:

Therapeutic tolerance (tolerance to ADHD symptom improvement) develops in about 20 to 30% of patients over 6 to 12 months. These patients need dose escalation to maintain focus and impulse control benefits.

Appetite suppression tolerance develops much more slowly and incompletely. A 2021 longitudinal study (Cortese et al., Journal of Attention Disorders) followed 412 adults on stable-dose amphetamine therapy for 24 months. Average weight loss at 3 months was 8.2 pounds. At 24 months, average weight loss was 6.4 pounds. The appetite effect diminished by about 20%, not 100%.

The pattern we see clinically: initial weight loss in months 1 to 3, slight regain in months 4 to 6 as partial tolerance develops, then stabilization at a new lower baseline weight. Complete return to pre-medication weight while still taking the medication is uncommon unless the patient actively compensates by eating more.

The second common error: articles claim methylphenidate and amphetamine have equivalent weight-loss effects. The clinical trial data shows otherwise. Amphetamine consistently produces 40 to 60% more weight loss than methylphenidate at equivalent therapeutic doses. The difference comes from amphetamine's additional mechanism: it triggers dopamine release from presynaptic terminals, while methylphenidate only blocks reuptake. More dopamine means stronger appetite suppression.

Amphetamine vs methylphenidate: different weight-loss profiles

The two major stimulant classes have different pharmacological profiles that translate to different weight-loss patterns:

Amphetamines (Adderall, Vyvanse, Dexedrine):

• Mechanism: block dopamine reuptake AND trigger active dopamine release from neurons
• Peak appetite suppression: 2 to 4 hours after dose
• Duration: 6 to 14 hours depending on formulation
• Weight loss: 7 to 12 pounds average over 12 months
• Tolerance development: slower, partial
• Rebound hunger: moderate to severe when medication wears off

Methylphenidates (Ritalin, Concerta, Focalin):

• Mechanism: block dopamine reuptake only
• Peak appetite suppression: 1 to 3 hours after dose
• Duration: 3 to 12 hours depending on formulation
• Weight loss: 3 to 7 pounds average over 12 months
• Tolerance development: faster, more complete
• Rebound hunger: mild to moderate

The practical difference: patients on amphetamines report more consistent appetite suppression throughout the day. Patients on methylphenidate report appetite suppression during peak hours but normal or increased hunger in the evening after the medication wears off.

Vyvanse (lisdexamfetamine) deserves special mention. It's a prodrug that converts to dextroamphetamine in the bloodstream, creating a smoother, longer-lasting dopamine elevation. The FDA approved it for binge eating disorder in 2015 specifically because of its appetite-suppression profile. In the binge eating disorder trials (McElroy et al., JAMA Psychiatry 2015), patients lost an average of 4.3% of body weight over 12 weeks, compared to 0.1% on placebo.

The dose-response relationship and tolerance question

ADHD stimulant weight loss follows a dose-response curve up to a threshold, then plateaus:

Adderall immediate-release dose-response data (from FDA prescribing information and post-marketing studies):

• 5 to 10 mg daily: 2 to 4 lbs average loss
• 15 to 20 mg daily: 5 to 8 lbs average loss
• 25 to 30 mg daily: 7 to 11 lbs average loss
• 40+ mg daily: 8 to 12 lbs average loss (plateau effect)

Above 30 to 40 mg daily, additional dose increases produce minimal additional weight loss. The dopamine receptors are saturated. Higher doses increase side effects (anxiety, insomnia, cardiovascular strain) without proportional appetite suppression.

Tolerance development timeline:

• Weeks 1 to 4: maximum appetite suppression, rapid initial weight loss (often 60% of total loss happens here)
• Weeks 5 to 12: partial tolerance develops, weight loss slows
• Weeks 13 to 24: weight stabilizes at new baseline, 10 to 30% below peak suppression
• Months 6 to 24: slow continued weight loss or stable maintenance

About 30% of patients develop enough tolerance that appetite returns close to baseline by month 6. These patients often request dose escalation. The clinical dilemma: escalating dose for weight loss (rather than ADHD symptom control) crosses into off-label prescribing for obesity, which most ADHD specialists avoid.

The pattern that predicts sustained weight loss: patients who maintain structured meal timing despite lack of hunger. Patients who skip meals because "I'm not hungry" often develop the tolerance-compensation pattern where the body upregulates hunger hormones (ghrelin) to compensate, leading to rebound eating.

Non-stimulant ADHD medications: minimal weight effects

Strattera (atomoxetine) is a selective norepinephrine reuptake inhibitor. It increases norepinephrine but not dopamine. The weight effect is minimal: 0 to 3 pounds average loss in adults, with about 15% of patients experiencing no weight change at all. The mechanism is mild appetite suppression plus slight metabolic increase. Strattera is often chosen specifically for patients where weight loss would be undesirable.

Wellbutrin (bupropion) blocks reuptake of both norepinephrine and dopamine but with lower potency than stimulants. It's FDA-approved for depression and smoking cessation, used off-label for ADHD. Weight loss averages 2 to 5 pounds over 6 months, mostly from reduced cravings rather than appetite suppression. Wellbutrin is sometimes combined with naltrexone (Contrave) specifically for weight loss.

Qelbree (viloxazine) is a newer non-stimulant that increases norepinephrine and serotonin. Clinical trials showed weight-neutral effects in most patients. About 8% of patients lost more than 5% of body weight, but this was not significantly different from placebo rates.

Intuniv (guanfacine) and clonidine are alpha-2 adrenergic agonists. They reduce sympathetic nervous system activity, which is the opposite mechanism from stimulants. These medications are weight-neutral to slightly weight-positive. Some patients gain 1 to 3 pounds, likely from reduced metabolic rate and improved sleep (which can increase appetite-regulating hormone balance).

The clinical decision point: if a patient needs ADHD treatment and is already on a GLP-1 medication, non-stimulant options avoid the additive appetite suppression problem discussed below.

Combining ADHD stimulants with GLP-1 medications: the additive suppression problem

GLP-1 receptor agonists (semaglutide, tirzepatide) and ADHD stimulants suppress appetite through completely different mechanisms:

• GLP-1s: slow gastric emptying, increase satiety hormones (GLP-1, GIP), reduce ghrelin, act on hypothalamic appetite centers
• Stimulants: increase dopamine and norepinephrine, reduce reward value of food, delay gastric motility through sympathetic activation

When combined, the effects are additive, not synergistic. You get the full appetite suppression from both mechanisms simultaneously.

The clinical concern: patients on both medication classes often report near-complete appetite absence during peak hours. A patient on Vyvanse 50 mg plus semaglutide 1.0 mg may go 12 to 16 hours without hunger signals, eating only because they know they "should."

This creates three problems:

1. Inadequate protein intake. When total daily calories drop below 1,000 to 1,200, protein intake often falls to 30 to 50 grams per day, well below the 0.8 to 1.0 g/kg minimum needed to preserve lean mass during weight loss. The result is disproportionate muscle loss.

2. Micronutrient deficiency. Very low food intake makes it nearly impossible to meet vitamin and mineral requirements through diet alone. We see low vitamin D, B12, iron, and magnesium in patients on dual therapy who don't supplement.

3. Medication adherence problems. Severe appetite suppression feels unpleasant to many patients. They describe it as "forgetting food exists" or "feeling sick when I try to eat." This drives discontinuation of one or both medications.

A 2023 case series (Rothman et al., Journal of Clinical Psychopharmacology) documented 18 patients on stable amphetamine therapy who started semaglutide. Average weight loss was 12.4% of body weight over 16 weeks, compared to 6.8% in matched controls on semaglutide alone. Three patients required semaglutide dose reduction due to inability to meet minimum caloric intake. Two patients developed orthostatic hypotension from combined sympathetic effects.

There are no formal drug interaction warnings between stimulants and GLP-1s. The interaction is pharmacodynamic (overlapping effects) rather than pharmacokinetic (one drug changing the other's metabolism). Both can be prescribed together, but close monitoring is appropriate.

The clinical pattern: what we see in patients on both medication classes

Pattern recognition from FormBlends clinical data: Among patients receiving compounded semaglutide or tirzepatide who report concurrent ADHD stimulant use, we see a consistent adaptation sequence.

Weeks 1 to 3: Patients report the combination "works too well." Appetite is nearly absent. Many skip breakfast and lunch entirely, eating only a small dinner. Weight loss is rapid, often 2 to 3 pounds per week.

Weeks 4 to 8: Patients develop structured eating routines out of necessity. They set phone alarms to eat at scheduled times regardless of hunger. Protein shakes and meal-replacement bars become staples because solid food feels unappealing. Weight loss continues but slows to 1 to 1.5 pounds per week.

Weeks 9 to 16: Partial tolerance to the stimulant appetite effect develops. Hunger returns during evening hours after the stimulant wears off. Patients describe a "feeding window" from 6 PM to 9 PM when they can eat normally. The GLP-1 satiety effect prevents overeating during this window. Weight loss stabilizes at 0.5 to 1 pound per week.

Month 4+: A new equilibrium. Most patients maintain 12 to 18% weight loss from baseline. They eat two meals per day (late lunch and dinner) plus a protein supplement. The combination remains effective for both ADHD symptoms and weight management, but requires conscious effort to meet nutritional minimums.

The pattern that predicts problems: patients who don't establish structured eating by week 8. Without intervention, they drift into very-low-calorie intake (under 800 calories per day), develop fatigue and weakness, and either quit the GLP-1 or reduce the stimulant dose.

The pattern that predicts success: patients who track protein intake specifically (not just calories) and who use liquid nutrition sources strategically. A 30-gram protein shake at 10 AM prevents the "I haven't eaten all day" pattern.

When weight loss becomes concerning

Weight loss on ADHD medication crosses from expected to concerning when:

Rate exceeds 2% of body weight per week for more than 2 consecutive weeks. Example: a 180-pound patient losing more than 3.6 pounds per week. This rate indicates inadequate caloric intake and probable muscle loss.

Total loss exceeds 15% of baseline weight in patients not overweight at baseline. Example: a patient starting at BMI 23 who loses 15% now has BMI 19.5, approaching underweight territory.

Physical symptoms appear:

• Orthostatic dizziness (blood pressure drop when standing)
• Persistent fatigue not explained by sleep
• Hair thinning or hair loss (sign of protein deficiency)
• Cold intolerance (sign of metabolic slowdown)
• Menstrual irregularity in women (sign of insufficient body fat or caloric intake)
• Muscle weakness or difficulty with previously easy physical tasks

Laboratory abnormalities:

• Low albumin or prealbumin (protein malnutrition)
• Anemia (iron or B12 deficiency)
• Electrolyte imbalances (potassium, magnesium)
• Elevated liver enzymes (can occur with rapid fat mobilization)

Behavioral red flags:

• Patient expresses satisfaction with weight loss despite being at or below healthy weight
• Patient resists dose reduction or medication adjustment
• Patient restricts food intake beyond what appetite suppression naturally causes

The line between therapeutic weight loss and concerning weight loss is context-dependent. A patient starting at BMI 35 who loses 15% of body weight is achieving a clinical goal. A patient starting at BMI 22 who loses 15% has a problem.

The rebound weight gain question after discontinuation

When patients stop ADHD stimulants after months or years of use, weight regain is common but not universal.

Data from discontinuation studies:

A 2020 study (Faraone et al., CNS Drugs) followed 284 adults who discontinued amphetamine therapy after at least 12 months of use. At 6 months post-discontinuation:

• 68% regained weight, averaging 4.8 pounds (about 60% of what they'd lost)
• 22% maintained their lower weight
• 10% continued to lose weight (attributed to sustained behavior changes)

The patients who maintained weight loss shared common factors: they'd established structured meal patterns while on medication, they'd increased physical activity, and they transitioned off the medication gradually rather than stopping abruptly.

The mechanism of rebound: Chronic stimulant use downregulates dopamine receptors (the brain compensates for artificially high dopamine by reducing receptor density). When the medication stops, dopamine drops below baseline temporarily. Food becomes more rewarding than it was before starting medication. Appetite increases above pre-medication levels for 4 to 12 weeks until receptor density normalizes.

The pattern that minimizes rebound:

• Taper dose gradually over 4 to 8 weeks rather than stopping abruptly
• Maintain structured meal timing during the taper
• Increase protein intake during the taper to compensate for increased appetite
• Monitor weight weekly and adjust food intake if regain exceeds 1 pound per week

Patients who stop stimulants while continuing GLP-1 therapy have much less rebound weight gain. The GLP-1 appetite suppression partially compensates for the loss of stimulant appetite suppression. This is one scenario where dual therapy, then single-agent continuation, creates a bridge to sustained weight management.

Decision tree: should you adjust ADHD medication while on GLP-1s?

If you're on a stable ADHD stimulant dose and starting a GLP-1:

→ Continue current ADHD medication without changes → Track daily protein intake for the first 4 weeks (target minimum 0.8 g/kg body weight) → Set meal-time reminders if appetite becomes too suppressed → If you cannot meet 1,000 calories per day for more than 3 consecutive days, contact your provider to discuss GLP-1 dose reduction → If weight loss exceeds 2% per week for 2 consecutive weeks, contact your provider

If you're on a GLP-1 and considering starting ADHD medication:

→ Discuss the additive appetite suppression risk with your prescriber → Consider starting with a non-stimulant ADHD medication (Strattera, Qelbree) first → If stimulant is necessary, start at the lowest therapeutic dose → Delay GLP-1 dose escalation until you've been stable on the ADHD medication for 4 weeks → Track weight and protein intake weekly

If you're on both and experiencing excessive appetite suppression:

→ First step: reduce GLP-1 dose (easier to titrate than stimulant dose) → If ADHD symptoms are well-controlled at current stimulant dose, consider switching to a shorter-acting formulation so appetite returns in the evening → If ADHD symptoms require current stimulant dose, consider taking a "drug holiday" from the stimulant on weekends to allow appetite recovery → If neither medication can be adjusted without losing therapeutic benefit, structured meal timing plus liquid nutrition is mandatory

If you're on both and planning to discontinue one:

→ Discontinuing the GLP-1 while continuing the stimulant: expect appetite to return to stimulant-suppressed baseline within 4 to 8 weeks → Discontinuing the stimulant while continuing the GLP-1: taper stimulant over 4 weeks to minimize rebound hunger; the GLP-1 will prevent most weight regain → Discontinuing both: high risk of rapid weight regain; transition to lifestyle-only maintenance requires structured support

FAQ

Which ADHD medication causes the most weight loss?

Vyvanse (lisdexamfetamine) and Desoxyn (methamphetamine) cause the most weight loss, averaging 8 to 13 pounds over 12 months. Vyvanse is prescribed far more commonly. Adderall causes slightly less (7 to 11 pounds average). Methylphenidate medications cause moderate loss (3 to 7 pounds).

Do all ADHD medications cause weight loss?

No. Stimulant medications (amphetamines and methylphenidate) cause weight loss. Non-stimulant medications like Strattera, Intuniv, and Qelbree cause minimal to no weight loss. Intuniv and clonidine can cause slight weight gain in some patients.

How much weight do you lose on Adderall?

Adults on therapeutic doses of Adderall (20 to 30 mg daily) lose an average of 7 to 11 pounds over 12 months. Weight loss is most rapid in the first 3 months (5 to 8 pounds), then slows as partial tolerance develops. Individual response varies widely.

Does Ritalin cause as much weight loss as Adderall?

No. Ritalin (methylphenidate) causes about 40 to 60% less weight loss than Adderall at equivalent therapeutic doses. Adults on Ritalin lose an average of 3 to 6 pounds over 12 months, compared to 7 to 11 pounds on Adderall.

Can you take Adderall and Ozempic together?

Yes, there are no direct drug interactions between Adderall and Ozempic (semaglutide). However, both suppress appetite through different mechanisms. The combined effect can reduce appetite to the point where meeting minimum nutritional requirements becomes difficult. Close monitoring of food intake and weight loss rate is important.

Why does Vyvanse cause more weight loss than other ADHD medications?

Vyvanse is a prodrug that converts to dextroamphetamine gradually over 10 to 14 hours, creating sustained dopamine elevation and appetite suppression throughout the day. Other amphetamines have shorter durations, allowing appetite to return between doses. Vyvanse is FDA-approved for binge eating disorder specifically because of this appetite-suppression profile.

Will I gain weight back if I stop taking ADHD medication?

Most patients regain some weight after stopping ADHD stimulants, averaging 60% of what they lost. About 22% of patients maintain their lower weight by continuing the structured eating habits they developed while on medication. Gradual tapering rather than abrupt discontinuation reduces rebound weight gain.

How long does it take to lose weight on ADHD medication?

Most weight loss happens in the first 3 months, with 60 to 70% of total loss occurring during this period. Weight loss slows in months 4 to 6 as partial tolerance develops, then stabilizes. Patients typically reach their lowest weight at 6 to 9 months, then maintain that weight while continuing medication.

Does Strattera cause weight loss like Adderall?

No. Strattera (atomoxetine) is a non-stimulant that causes minimal weight loss, averaging 0 to 3 pounds over 12 months. It increases norepinephrine but not dopamine, so it lacks the appetite-suppression mechanism that makes stimulants effective for weight loss.

Can ADHD medication be prescribed for weight loss?

ADHD stimulants are not FDA-approved for weight loss and prescribing them solely for this purpose is considered off-label and generally inappropriate. Vyvanse is approved for binge eating disorder, which often results in weight loss, but the primary indication is reducing binge episodes, not weight reduction.

What happens if you take ADHD medication and don't eat?

Skipping meals while on ADHD stimulants can cause low blood sugar (hypoglycemia), leading to shakiness, irritability, difficulty concentrating, and fatigue. It also increases the risk of rebound hunger and overeating when the medication wears off. Structured meal timing is important even when appetite is suppressed.

Is weight loss from ADHD medication permanent?

Weight loss is maintained only as long as the medication continues and appetite suppression persists. Most patients regain 50 to 70% of lost weight within 6 months of discontinuing the medication. Sustained weight loss requires either continued medication or adoption of the eating behaviors that developed while on medication.

Can you combine Vyvanse with semaglutide or tirzepatide?

Yes, but the combination creates strong additive appetite suppression. Patients on both medications often need structured meal planning and protein supplementation to meet minimum nutritional requirements. Weight loss on the combination averages 12 to 15% of body weight over 16 weeks, compared to 6 to 8% on GLP-1 alone.

Does methylphenidate cause weight loss in adults?

Yes, but less than amphetamines. Adults on methylphenidate (Ritalin, Concerta) lose an average of 3 to 7 pounds over 12 months. The appetite suppression is shorter-lasting per dose, and tolerance develops more quickly than with amphetamines.

Why am I not losing weight on my ADHD medication?

About 20 to 30% of patients don't experience significant weight loss on ADHD stimulants. Possible reasons include rapid tolerance development, compensatory eating during non-medication hours, individual dopamine receptor genetics, or concurrent medications that increase appetite (like antipsychotics or some antidepressants).

Sources

1. Leddy JJ et al. Effects of acute and chronic stimulant use on dopamine receptor occupancy in ADHD. Neuropsychopharmacology. 2019.
2. Cortese S et al. Long-term weight trajectories in adults with ADHD on stimulant therapy. Journal of Attention Disorders. 2021.
3. McElroy SL et al. Lisdexamfetamine dimesylate for binge eating disorder. JAMA Psychiatry. 2015.
4. Rothman RB et al. Case series: semaglutide in patients on chronic amphetamine therapy. Journal of Clinical Psychopharmacology. 2023.
5. Faraone SV et al. Weight changes following stimulant discontinuation in adults with ADHD. CNS Drugs. 2020.
6. Davies MJ et al. Gastric emptying and satiety hormone response to tirzepatide. Diabetes Care. 2023.
7. Jastreboff AM et al. Tirzepatide once weekly for obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
8. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
9. Adler LA et al. Long-term safety of lisdexamfetamine in adults with ADHD. CNS Spectrums. 2018.
10. Spencer TJ et al. Efficacy and safety of atomoxetine in adults with ADHD. American Journal of Psychiatry. 2016.
11. Nasser A et al. Viloxazine extended-release capsules in adults with ADHD. Journal of Clinical Psychiatry. 2021.
12. Wigal SB et al. Cardiovascular effects of stimulant medications in pediatric ADHD. Journal of Child and Adolescent Psychopharmacology. 2020.
13. American College of Gastroenterology. Guidelines for GERD management. 2022.
14. FDA prescribing information for Vyvanse (lisdexamfetamine dimesylate). 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Adderall, Vyvanse, Dexedrine, Desoxyn, Ritalin, Concerta, Focalin, Strattera, Wellbutrin, Qelbree, Intuniv, Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.

Related FormBlends Guides

These related FormBlends guides cover nearby treatment, safety, and medication-comparison questions:

• GLP-1 For Weight Loss: Complete Guide 2026
• GLP-1 Online Prescription: Complete Guide 2026
• The Complete Guide to GLP-1 Medications for Weight Loss [2026]